Acute Leukemia in a Patient with Sickle-Cell Anemia Treated with Hydroxyurea
Authors: Scott Wilson
Journal: Annals of Internal Medicine (2000)

Letters5 December 2000Acute Leukemia in a Patient with Sickle-Cell Anemia Treated with HydroxyureaScott Wilson, MDScott Wilson, MDEl Rio Health Center; Tucson, AZ 85745 (Wilson)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-133-11-200012050-00029 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:Sickle-cell disease is rarely associated with hematogenous malignancy. Hydroxyurea can reduce the frequency of painful crises in sickle-cell disease; its leukemogenic potential is uncertain. We report a case of acute myelogenous leukemia in a patient with sickle-cell disease treated with hydroxyurea.In May 1999, a 42-year-old woman with sickle-cell anemia was admitted with recurrent pain. She had been treated with hydroxyurea since April 1993. In April 1998, hemoglobin electrophoresis demonstrated a hemoglobin A2 level of 0.017, a fetal hemoglobin level of 0.38, and a hemoglobin S level of 0.60. On admission, the hematocrit was 0.17, the mean ...References1. Najean Y, Rain JD. Treatment of polycythemia vera: use of 32P alone or in combination with maintenance therapy using hydroxyurea in 461 patients greater than 65 years of age. The French Polycythemia Study Group. Blood. 1997;89:2319-27. CrossrefMedlineGoogle Scholar2. Sterkers Y, Preudhomme C, Lai JL, Demory JL, Caulier MT, Wattel E, et al . Acute myeloid leukemia and myelodysplastic syndromes following essential thrombocythemia treated with hydroxyurea: high proportion of cases with 17p deletion. Blood. 1998;91:616-22. CrossrefMedlineGoogle Scholar3. Rauch A, Borromeo M, Ghafoor A, Khoyratty B, Maheshwari J. Leukemogenesis of hydroxyurea in the treatment of sickle cell anemia [Abstract]. Blood. 1999;94 Suppl 1 415a. Google Scholar4. Charache S, Terrin ML, Moore RD, Dover GJ, Barton FB, Eckert SV, et al . Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. N Engl J Med. 1995;332:1317-22. CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAffiliations: El Rio Health Center; Tucson, AZ 85745 (Wilson) PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited ByMyeloid neoplasms in the setting of sickle cell disease: an intrinsic association with the underlying condition rather than a coincidence; report of 4 cases and review of the literatureOccurrence of acute myeloid leukemia in hydroxyurea-treated sickle cell disease patientComorbidities in aging patients with sickle cell diseaseAccelerated leukemic transformation after haplo-identical transplantation for hydroxyurea-treated sickle cell diseaseIncreased risk of leukemia among sickle cell disease patients in CaliforniaHydroxycarbamide treatment in sickle cell disease: estimates of possible leukaemia risk and of hospitalization survival benefitDevelopment of Myelodysplastic Syndrome and Acute Myeloid Leukemia 15 Years after Hydroxyurea Use in a patient with sickle Cell AnemiaCurrent strategies for the management of children with sickle cell diseaseHodgkin lymphoma in a sickle cell anaemia child treated with hydroxyureaThe pharmacotherapy of sickle cell diseasePharmacotherapy of essential thrombocythemiaSystematic Review: Hydroxyurea for the Treatment of Adults with Sickle Cell DiseaseSophie Lanzkron, MD, John J. Strouse, MD, Renee Wilson, MSc, Mary Catherine Beach, MD, MPH, Carlton Haywood, MA, HaeSong Park, MD, MPH, Catherine Witkop, MD, MPH, Eric B. Bass, MD, MPH, and Jodi B. Segal, MD, MPHTraitement des patients drépanocytaires par hydroxyurée : efficacité et toléranceDNA damage in blood leukocytes of individuals with sickle cell disease treated with hydroxyureaDecreased transfusion needs associated with hydroxyurea therapy in Algerian patients with thalassemia major or intermediaModern treatment of thalassaemia intermediaParents' Assessment of Risk in Sickle Cell Disease Treatment With HydroxyureaNew Therapies for Sickle Cell DiseaseHydroxyurea therapy for sickle cell disease in community-based practices: A survey of Florida and North Carolina hematologists/oncologistsder(8)t(1;8) in myeloblastic transformation of ET with hydroxyurea as the sole prior treatmentA critical review of anagrelide therapy in essential thrombocythemia and related disordersMalignancy in patients with sickle cell diseaseMalignancies in sickle cell disease patients treated with hydroxyureaAcute leukemia and myelodysplasia in patients with a Philadelphia chromosome negative chronic myeloproliferative disorder treated with hydroxyurea alone or with hydroxyurea after busulphanThe role of hydroxyurea in the management of sickle cell diseasePathophysiological-Based Approaches to Treatment of Sickle Cell DiseaseThe role of hydroxyurea in sickle cell diseaseHydroxyurea treatment of sickle cell anemia in hospital-based practicesDeveloping treatment for sickle cell diseasePharmacologic Modulation of Fetal Hemoglobin 5 December 2000Volume 133, Issue 11Page: 925-926KeywordsAcute myeloid leukemiaAnemiaBloodBone marrowHemoglobinPlateletsPolycythemiaRespiratory failureSubarachnoid hemorrhageThrombocytosis ePublished: 5 December 2000 Issue Published: 5 December 2000 CopyrightCopyright © 2000 by American College of Physicians. All Rights Reserved.PDF DownloadLoading ...